Closing Pharma's intent-to-impact gap

$1 billion in earned commercial value. ~$450 million realized.
The rest leaked through prior authorization, affordability barriers, and handoffs no one owns.

Wayne Simmons spent over two decades inside pharma commercial operations at Pfizer and Bayer, watching the same structural failure repeat itself. The commercial model is highly optimized to generate prescribing intent. What it was never designed to do is govern what happens next.

What you'll take from this paper

• The Value Leakage Ladder: how compounding drop-off reduces $1B earned to ~$450M realized, and where in the system it happens

• Why the commercial model leaks value by design, and why the usual responses don't change that

• The FieldOS Three-Path Framework: governing the path to prescribe, path to fulfill, path to adhere simultaneously

• What changes when progression becomes observable and measurable: for field teams, management, and forecasting

• Diagnostic questions to identify where your commercial architecture is leaking value today

About the author

Wayne Simmons brings more than two decades of pharma commercial leadership, including global roles at Pfizer and Bayer. TheyDo is trusted by enterprise commercial teams at Lufthansa, Shell, and leading life sciences organizations worldwide.

Closing pharma’s intent-to-impact gap is a co-authored paper by Wayne Simmons, The Customer Excellence Agency, and TheyDo.